VACC vs. SKYE, SBTX, NKTX, NBTX, URGN, QTTB, AVIR, VTYX, KMDA, and LLY
Should you be buying Vaccitech stock or one of its competitors? The main competitors of Vaccitech include Skye Bioscience (SKYE), Silverback Therapeutics (SBTX), Nkarta (NKTX), Nanobiotix (NBTX), UroGen Pharma (URGN), Q32 Bio (QTTB), Atea Pharmaceuticals (AVIR), Ventyx Biosciences (VTYX), Kamada (KMDA), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceutical preparations" industry.
Vaccitech (NASDAQ:VACC) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.
26.1% of Vaccitech shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 6.0% of Vaccitech shares are owned by insiders. Comparatively, 0.7% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Vaccitech has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500.
In the previous week, Skye Bioscience had 6 more articles in the media than Vaccitech. MarketBeat recorded 7 mentions for Skye Bioscience and 1 mentions for Vaccitech. Skye Bioscience's average media sentiment score of 0.55 beat Vaccitech's score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the news media.
Vaccitech received 15 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 70.83% of users gave Vaccitech an outperform vote.
Vaccitech presently has a consensus target price of $7.63, suggesting a potential upside of 237.43%. Skye Bioscience has a consensus target price of $22.00, suggesting a potential upside of 78.86%. Given Vaccitech's higher probable upside, analysts plainly believe Vaccitech is more favorable than Skye Bioscience.
Vaccitech has higher revenue and earnings than Skye Bioscience.
Skye Bioscience has a net margin of 0.00% compared to Vaccitech's net margin of -409.18%. Vaccitech's return on equity of -23.41% beat Skye Bioscience's return on equity.
Summary
Vaccitech beats Skye Bioscience on 8 of the 15 factors compared between the two stocks.
Get Vaccitech News Delivered to You Automatically
Sign up to receive the latest news and ratings for VACC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VACC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vaccitech Competitors List
Related Companies and Tools
